Anixa Biosciences Says USAN Council Approves liraltagene autoleucel For Non-Proprietary Name Of Company's FSHR-Targeted CAR-T Therapy For Recurrent Ovarian Cancer

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Adopted Names (USAN) Council approved "liraltagene autoleucel" for the non-proprietary name of the Company's novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer. This U.S. approval follows the earlier approval for international use of the name by the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO). The USAN and INN nomenclature schemes for CAR-T cell therapies follow a two-word structure describing the gene and cell component.